TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04225208
Drug: [14C]-AZD4205, single 50 mg oral dose administrated on day 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive 50 mg AZD4205 oral solution (free base equivalent) containing a nominal dose of 15 µCi \[14C\]- radiolabelled AZD4205 as a single administration .
Study: NCT02579642
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline administered with usual induction drugs for ECT
Study: NCT01777919
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00206648
Drug: Betaferon/Betaseron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaseron 250 µg SC every other day
Study: NCT00206648
Drug: Betaferon/Betaseron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avonex 30 µg IM once per week
Study: NCT02648698
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin Tab and Tinidazole Tab are combined in the antibiotic group
Study: NCT06201182
Drug: Placebo via rectal enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo via rectal enema
Study: NCT06201182
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules given twice daily for 2 consecutive days
Study: NCT03844763
Drug: CTX
Normalized name: CTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTX: 50 mg Daily untill PD or major toxicity
Study: NCT03870763
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT02516618
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00116805
Drug: TDF placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily
Study: NCT00116805
Drug: ADV placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet administered orally once daily
Study: NCT00116805
Drug: FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
Study: NCT02740127
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine 1:400,000 by bolus injection given by anesthesiologist in OR.
Study: NCT01772433
Drug: Phonophoresis gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phonophoresis with base gel for 10 days, daily
Study: NCT03251287
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral matching placebo
Study: NCT00377234
Drug: ibandronate [Bonviva/Boniva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg po monthly for 3 months
Study: NCT00492349
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 0.5mg po qd x 7 days then titrated to Placebo 0.5mg po bid x 7 weeks
Study: NCT01495065
Drug: GSK2251052 750 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A: 750 mg IV GSK2251052 single dose
Study: NCT01495065
Drug: GSK2251052 1500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B: 1500 mg IV GSK2251052 single dose
Study: NCT01495065
Drug: GSK2251052 1500 mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C: 1500 mg IV GSK2251052 BID or placebo for 12 days
Study: NCT01495065
Drug: GSK2251052 2250 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment D: On Day 1 a single dose of GSK2251052 2250 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 2250 mg IV (for 9 days), fasted
Study: NCT01495065
Drug: GSK2251052 3000 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment E: On Day 1 a single dose of GSK2251052 3000 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 3000mg IV (for 9 days), fasted
Study: NCT01495065
Drug: GSK2251052 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment P: On Day 1 a single dose of 0.9% saline IV administered over 60 minutes; On Days 4 - 12 BID doses of 0.9% saline (for 9 days), fasted
Study: NCT02156674
Drug: Naglazyme®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg per kg of body weight administered once weekly as an intravenous infusion
Study: NCT03019536
Drug: LY3303560 - IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT03019536
Drug: Placebo - IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT03019536
Drug: Florbetapir F 18
Normalized name: Florbetapir F 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV during the Positron Emission Tomography (PET) scan performed during screening.
Study: NCT01490632
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01989234
Drug: YKP10811
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01989234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00426517
Drug: Campath 1H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditioning with Campath 1 mg/kg total dose given intravenously over 5 days
Study: NCT04255836
Drug: the first line chemotherapy for metastatic NSCLC
Approvals — FDA: no, EMA: no, PMDA: no
Description: paclitaxel+carboplatin or pemetrexed+cisplatin
Study: NCT04387136
Drug: Sublingual Sufentanil
Normalized name: sufentanil Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-30 minutes prior to planned emergence from anesthesia patients will either receive 30 mcg of sublingual sufentanil dispensed by the anesthesia provider.
Study: NCT00001165
Drug: combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00007904
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide 700 mg/m2 daily for 3 day every 3 weeks cycles 1-3
Study: NCT00007904
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients then receive doxorubicin IV on day 1.
Study: NCT04480242
Drug: Inhaled Corticosteroids (ICs)
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any corticosteroid (beclomethasone, budesonide, ciclesonide, fluticasone propionate, fluticasone furoate, mometasone, and triamcinolone) prescribed by the pediatrician as an inhaled controller medication, for daily management of asthma. The daily dose of ICs prescribed will be translated into beclomethasone equivalent.
Study: NCT04480242
Drug: Fixed-Dose Combination of Inhaled Corticosteroids and Long- Acting Beta-agonist (ICs/LABA)
Normalized name: Sinex Long-Acting Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone/formoterol, budesonide/formoterol, fluticasone furoate/vilanterol, fluticasone propionate/formoterol, fluticasone propionate/salmeterol, and mometasone/formoterol. Any of these combinations prescribed by the pediatrician as an inhaled controller medication, for daily management of asthma.
Study: NCT04480242
Drug: Other treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose oral corticosteroids, long-acting muscarinic antagonist (tiotropium), low-dose macrolides (azithromycin), leukotrienes receptor antagonists (i.e. montelukast), or biologic agents (i.e. omalizumab).
Study: NCT00186056
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive placebo tab
Study: NCT01387568
Drug: saline Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: children in group P received i.v. saline 0.9% 1 ml/kg followed by infusion at 0.1 ml. kg-1.h-1,and were continued up to 6 hours postoperatively
Study: NCT02170805
Drug: BIBR 1048 MS capsule formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBR 1048 MS, formulation B 50 mg
Study: NCT01313520
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL of 0.9% sodium chloride at Weeks 0, 2, 6, 14 via intravenous infusion
Study: NCT02175433
Drug: AGS67E
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous (IV) infusion
Study: NCT01919008
Drug: FK949E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT00423085
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo transdermal patch was provided in the following sizes: 2.5 cm\^2, 5 cm\^2, 7.5 cm\^2 and 10 cm\^2. The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day.
Study: NCT02365493
Drug: Beta-Lactam
Normalized name: Beta-lactam
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03370887
Drug: AZD8601
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8601 solution for injection, 0,5 mg/mL and 5 mg/mL will be given as 30 injections of 0.1 mg (3 mg per patient), or 1 mg (30 mg per patient) respectively on a single occasion
Study: NCT03370887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for AZ8601 injection for solution will be given as 30 injections per patient on a single occasion
Study: NCT04046874
Drug: Usual Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain Medication, imaging, referrals to other health services, other health care appointments
Study: NCT00933231
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV and Oral
Study: NCT04357028
Drug: Measles-Mumps-Rubella Vaccine
Normalized name: MEASLES/MUMPS/RUBELLA VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles mumps Rubella vaccine is a weak attenuated life vaccine
Study: NCT04357028
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm
Study: NCT01968213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
Study: NCT00969033
Drug: CS-1008
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-1008
Study: NCT02105948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile 0.9% sodium chloride solution
Study: NCT02576067
Drug: Low dose methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Study participants will additionally receive 1 mg daily oral folate.
Study: NCT02576067
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01324492
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03500874
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin 200mg/m2 ivd over 2 hours on Day 1
Study: NCT03500874
Drug: 5FU
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.
Study: NCT03325712
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT00202163
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02163993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SQ
Study: NCT01487096
Drug: Placebo (placebo for teriflunomide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: film-coated tablet~oral administration
Study: NCT00017381
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00760864
Drug: TAK-715 and methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TAK-715 25 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
Study: NCT00760864
Drug: TAK-715 and methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TAK-715 50 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
Study: NCT00760864
Drug: TAK-715 and methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TAK-715 100 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
Study: NCT00760864
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TAK-715 placebo-matching, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks
Study: NCT02808455
Drug: (Treatment A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four 100-mg capsules of pacritinib administered as a single oral dose
Study: NCT02808455
Drug: (Treatment B)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 80-mg oral solution dose of pacritinib
Study: NCT04050293
Drug: SPN-538
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive SPN-538
Study: NCT04050293
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Placebo
Study: NCT02936557
Drug: BAY987521
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z09-054)
Study: NCT03355079
Drug: SmofKabiven® E
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the intervention arm, SmofKabiven® E, with or without addition of Suppliven®, Vitalipid® Adult and/or Soluvit®, will be administered in addition to standard of care oral nutrition as per dietary counseling, whereas in the control arm, oral nutrition as per dietary counseling is the primary nutritional support.
Study: NCT01638923
Drug: EV/DNG (Qlaira, Natazia, BAY86-5027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placebo. A blister card consists of 28 pills, taken orally once a day for 7 cycles of 28 days each.
Study: NCT01638923
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to be taken orally daily for 7 cycles of 28 days each.
Study: NCT00435370
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT05997004
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: After surgical creation of umbilical port Control group received injection normal saline 1ml.
Study: NCT01176903
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: pressurized metered dose inhaler
Study: NCT01808157
Drug: CT327 ointment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01808157
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03848533
Drug: melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The administration of melatonin will be indicated at night before bedtime to avoid alterations of the circadian cycle. It will be contained in bottles labeled Medication 2 to maintain the masking. This intervention will be indicated in two groups (Melatonin plus metformin and Melatonin plus placebo)
Study: NCT03848533
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo may be contained in bottles labeled Medication 1 or Medication 2 depending on the time of administration, and the group in which it is used. Placebo will be used in two groups (Melatonin plus placebo and Metformin plus placebo)
Study: NCT00506961
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg rosuvastatin for 4 weeks followed by rosuvastatin or another 12 weeks
Study: NCT00506961
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg simvastatin for 4 weeks followed by 40 mg simvastatin for another 8 weeks
Study: NCT01410448
Drug: Steroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids were administered according to local clinical practice.
Study: NCT04383912
Drug: Botox Injectable Product
Normalized name: Botox Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: The side randomized to receive treatment will be injected with onabotulinum toxin A. Wound healing, scar characteristics, and patient satisfaction will be assessed post operatively. Scarring will be assessed by the patient, medical observers and a lay observer, all masked to the treatment vs placebo side. Standardized scales will be used, and pre-operative, intra-operative, and post-operative photographs will be taken for all participants. ImageJ software will be used to analyze the photos and measure the degree of brow lift achieved on each side, to ensure this has not been affected by onabotulinum toxin injection.
Study: NCT02186951
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
Study: NCT04730297
Drug: paracetamol 500 mg plus codeine 30 mg preoperative administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: each patient 30 minutes before surgery received paracetamol 500 mg plus codeine 30 mg
Study: NCT04730297
Drug: ibuprofen 400 mg preoperative administration
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: each patient 30 minutes before surgery received ibuprofen 400 mg
Study: NCT04730297
Drug: Placebo oral tablet preoperative administration
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: each patient 30 minutes before surgery received placebo
Study: NCT00014378
Drug: Chinese Herb Huanglian (Coptis chinesis)
Normalized name: Coptis chinensis root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive capsules of the powdered extract of the huanglian root, which will take by mouth 4 times a day (qid).
Study: NCT04762147
Drug: paracetamol, the group P
Approvals — FDA: no, EMA: no, PMDA: no
Description: The paracetamol was administered 30 minutes before the start of surgery for intra-operative and post-operative analgesia in patients undergoing for hysteroscopy
Study: NCT02939937
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg phenytoin three time daily for three months, and phenytoin levels will be taken at one and three months later.
Study: NCT02939937
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg placebo three time daily for three months, and phenytoin levels will be taken at one and three months later.
Study: NCT00985556
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT02571569
Drug: BAY1093884
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single escalating dose with a starting dose of 0.3 mg/kg for the first cohort. Drug will be administered via IV infusion over 1 hour and SC injection. Based on safety, PK and PD results the doses for the other cohorts will be determined.
Study: NCT02571569
Drug: BAY1093884
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dose cohort with a single 150-mg SC injection once a week for 6 weeks.
Study: NCT00756886
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg QD for 7 days prior to surgery, and then continue at same dosage for 14 days after surgery.
Study: NCT04131517
Drug: Microgynon 30®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Medication: Microgynon 30® Dosage formulation: Oral tablets Dose: Ethinyl estradiol 30 µg + levonorgestrel 150 µg
Study: NCT02152592
Drug: PCM/Oxy1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled Release oxycodone 10 mg orally twice a day for 24 hours
Study: NCT02152592
Drug: PCM/Oxy2
Approvals — FDA: no, EMA: no, PMDA: no
Description: CR oxycodone 10 mg orally twice a day for 48 hours
Study: NCT00803010
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate: administered on day 1 at dose of 15 mg/m\^2, and a dose of 10 mg/m\^2 on days 3, 6, and 11. Dose can be adjusted for reduced creatinine clearance.
Study: NCT04479917
Drug: TPN171H
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
Study: NCT04479917
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form;tablets Route of administration:;oral;Administered 30 minutes to 4 hours prior to initiation of sexual activity for a duration of 8 weeks to use no more than one dose in any 24-hour period
Study: NCT01453569
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: simulant of sodium oligo-mannurarate capsule
Study: NCT00723411
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injected subcutaneously at days 1, 30, 90 and 270
Study: NCT01153191
Drug: sub-q gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mg/kg of gentamicin in 20 ml of sterile saline up to max dose of 120mg injected above the abdominal wall fascia- the length of the incision will be marked and injection made with intent being to evenly distribute the volume of injection in the subcutaneous tissues in immediate vicinity of and prior to the initial incision- analogous to the technique employed when using local anesthetic
Study: NCT01495338
Drug: AC-170 0.17%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in one eye at one timepoint
Study: NCT01495338
Drug: AC-170 0.24% (Formulation 1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in one eye at one timepoint
Study: NCT01490762
Drug: Technosphere Insulin Inhalation Powder using the Gen2C inhaler
Normalized name: insulin, regular, human Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation Powder
Study: NCT01490762
Drug: Regular Human Insulin
Normalized name: insulin, regular, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT02909972
Drug: ALRN-6924
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of ALRN-6924 per cohort, administered IV, Days 1, 8, and 15 every 28 days.
Study: NCT00681538
Drug: Sativex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum dose within any 24-hour interval is 12 sprays (THC 32.4 mg: CBD 30 mg)